DK1223925T3 - Fedtsyrederivat til behandling af eksterne sekretionslidelser - Google Patents

Fedtsyrederivat til behandling af eksterne sekretionslidelser

Info

Publication number
DK1223925T3
DK1223925T3 DK00944426T DK00944426T DK1223925T3 DK 1223925 T3 DK1223925 T3 DK 1223925T3 DK 00944426 T DK00944426 T DK 00944426T DK 00944426 T DK00944426 T DK 00944426T DK 1223925 T3 DK1223925 T3 DK 1223925T3
Authority
DK
Denmark
Prior art keywords
treatment
fatty acid
acid derivative
secretion disorders
external secretion
Prior art date
Application number
DK00944426T
Other languages
Danish (da)
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of DK1223925T3 publication Critical patent/DK1223925T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00944426T 1999-07-14 2000-07-13 Fedtsyrederivat til behandling af eksterne sekretionslidelser DK1223925T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14362799P 1999-07-14 1999-07-14
PCT/JP2000/004696 WO2001005388A2 (fr) 1999-07-14 2000-07-13 Composition destinee au traitement des troubles de la secretion externe

Publications (1)

Publication Number Publication Date
DK1223925T3 true DK1223925T3 (da) 2007-03-19

Family

ID=22504885

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00944426T DK1223925T3 (da) 1999-07-14 2000-07-13 Fedtsyrederivat til behandling af eksterne sekretionslidelser

Country Status (25)

Country Link
US (3) US6566398B1 (fr)
EP (1) EP1223925B1 (fr)
JP (2) JP4167828B2 (fr)
KR (1) KR100750553B1 (fr)
CN (4) CN100548977C (fr)
AR (2) AR029381A1 (fr)
AT (1) ATE344027T1 (fr)
AU (1) AU779936B2 (fr)
BR (1) BRPI0012387B1 (fr)
CA (1) CA2377661C (fr)
CZ (1) CZ303958B6 (fr)
DE (1) DE60031710T2 (fr)
DK (1) DK1223925T3 (fr)
ES (1) ES2273706T3 (fr)
HK (1) HK1048443B (fr)
HU (1) HU229318B1 (fr)
IL (2) IL147440A0 (fr)
MX (1) MXPA02000437A (fr)
NO (1) NO323908B1 (fr)
PT (1) PT1223925E (fr)
RU (1) RU2264816C2 (fr)
TR (1) TR200200065T2 (fr)
TW (1) TWI225398B (fr)
WO (1) WO2001005388A2 (fr)
ZA (1) ZA200109726B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
WO2003105823A1 (fr) * 2002-06-14 2003-12-24 Alcon, Inc. Utilisation de composes d'acide hydroxyeicosatetraenoique pour traiter la secheresse buccale
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
US20040185075A1 (en) 2003-01-31 2004-09-23 Maria Dalko Use of at least one (dihydro)jasmonic acid derivative for treating dry skin
FR2850571B1 (fr) * 2003-01-31 2006-07-07 Oreal Utilisation d'un derive d'acide(dihydro) jasmonique pour le traitement des peaux seches
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
JP4249185B2 (ja) 2003-10-06 2009-04-02 株式会社オフテクス 涙液異常の治療のための眼科用組成物
US7923471B2 (en) 2004-05-14 2011-04-12 Alcon, Inc. Method of treating dry eye disorders and uveitis
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
MX2007000208A (es) * 2004-07-01 2007-08-07 Schepens Eye Res Inst Composiciones y metodos para tratar trastornos y condiciones del ojo.
DK1841433T3 (da) * 2005-01-27 2012-01-16 Sucampo Ag Præparat til behandling af lidelser i centralnervesystemet
ATE489955T1 (de) * 2005-03-04 2010-12-15 Sucampo Ag Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
US7638142B2 (en) * 2005-10-12 2009-12-29 Vitamin Science, Inc. Therapeutic composition for the treatment of dry eye syndrome
NZ570190A (en) 2006-01-24 2011-03-31 Sucampo Ag Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
JP2010519177A (ja) * 2007-02-27 2010-06-03 スキャンポ・アーゲー ミトコンドリアを保護するための組成物および方法
US9161909B2 (en) 2007-08-24 2015-10-20 Axiomedic Ltd. Adhesive compositions for the treatment of xerostomia
US20090053309A1 (en) * 2007-08-24 2009-02-26 Axiomedic Ltd., Gibraltar Adhesive compositions for the treatment of xerostomia
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US9597278B2 (en) 2008-11-13 2017-03-21 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US9884082B2 (en) 2008-11-13 2018-02-06 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
EP2389939A1 (fr) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Utilisation de prostaglandines F2alpha et analogues pour la cicatrisation des lésions de la cornée et du conjonctif
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
WO2012068247A1 (fr) 2010-11-16 2012-05-24 The Board Of Trustees Of The Leland Stanford Junior University Systèmes et procédés pour traiter la sécheresse oculaire
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
RU2648474C2 (ru) * 2011-08-05 2018-03-26 Сукампо Аг Способ лечения шизофрении
WO2014159679A1 (fr) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Procédés pour utiliser la lubiprostone pour absorber un fluide depuis l'espace sous-rétinien
US8996137B2 (en) 2013-04-19 2015-03-31 Oculeve, Inc. Nasal stimulation devices and methods
KR20170074926A (ko) * 2014-10-22 2017-06-30 오큘레브, 인크. 안구 건조증을 치료하기 위한 자극 장치 및 방법
WO2017192572A1 (fr) 2016-05-02 2017-11-09 Oculeve, Inc. Stimulation intranasale pour le traitement de la maladie de la glande de meibomius et de la blépharite
JP7300446B2 (ja) 2018-04-26 2023-06-29 ライオン株式会社 外分泌促進剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49783B1 (en) 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
GB8319073D0 (en) 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
JPH0688966B2 (ja) * 1987-01-28 1994-11-09 株式会社アールテック・ウエノ プロスタグランジンｅ類およびそれを含む抗潰瘍剤
JPH07103096B2 (ja) * 1987-01-28 1995-11-08 株式会社上野製薬応用研究所 プロスタグランジンｄ類およびそれを含む鎮静・睡眠剤
DE3711164A1 (de) 1987-04-02 1988-10-20 Zeiss Carl Fa Steckelementeinrichtung zur halterung von bauteilen in stapeln
CA1324129C (fr) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandines de la serie f
JPS63277604A (ja) * 1987-05-11 1988-11-15 Showa Denko Kk α−リノレン酸含有化粧料
JPH0692305B2 (ja) * 1987-05-15 1994-11-16 株式会社上野製薬応用研究所 体温上昇剤
ATE108330T1 (de) 1987-09-18 1994-07-15 R Tech Ueno Ltd Hypotensive okulare mittel.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
WO1990001323A1 (fr) * 1988-08-12 1990-02-22 Bernstein Joel E Procede et composition de traitement et de prevention des problemes de peau seche
CA2027814C (fr) * 1989-10-20 1996-07-30 Ryuji Ueno Traitement d'une maladie hepatobiliaire a base de composes 5-cetoprostaglandin
TW249226B (fr) * 1990-04-04 1995-06-11 Aderk Ueno Kk
JPH07100655B2 (ja) * 1990-04-04 1995-11-01 株式会社アールテック・ウエノ 白内障処置剤
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
JPH07113012B2 (ja) * 1991-01-29 1995-12-06 株式会社アールテック・ウエノ 新規１５−ケト−プロスタグランジン類
ATE141794T1 (de) * 1991-03-14 1996-09-15 R Tech Ueno Ltd Stimulierung von wundheilung mit 15-keto- prostaglandinverbindungen
US5369127A (en) 1993-04-21 1994-11-29 Allergan, Inc. 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
CA2150287C (fr) 1994-06-03 2004-08-10 Ryuji Ueno Agent therapeutique pour les affections hepatobiliaires
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
WO2000038690A2 (fr) * 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Agonistes de prostaglandine e utilises dans le traitement de la keratoconjonctivite seche
WO2000038663A2 (fr) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Agonistes du recepteur ep4 utilises dans le traitement du syndrome sec
DK1841433T3 (da) * 2005-01-27 2012-01-16 Sucampo Ag Præparat til behandling af lidelser i centralnervesystemet
ATE489955T1 (de) * 2005-03-04 2010-12-15 Sucampo Ag Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten

Also Published As

Publication number Publication date
IL147440A0 (en) 2002-08-14
ZA200109726B (en) 2002-08-30
CN101829120A (zh) 2010-09-15
IL147440A (en) 2008-11-03
KR20020060149A (ko) 2002-07-16
CN101829120B (zh) 2013-09-18
US6566398B1 (en) 2003-05-20
NO20020133D0 (no) 2002-01-11
WO2001005388A3 (fr) 2002-05-10
BR0012387A (pt) 2002-03-26
RU2264816C2 (ru) 2005-11-27
CN101695495A (zh) 2010-04-21
US7396946B2 (en) 2008-07-08
JP2009007360A (ja) 2009-01-15
US20030171438A1 (en) 2003-09-11
HU229318B1 (hu) 2013-10-28
HUP0202400A3 (en) 2005-02-28
NO20020133L (no) 2002-03-13
NO323908B1 (no) 2007-07-16
AU5853300A (en) 2001-02-05
CA2377661A1 (fr) 2001-01-25
CZ2002133A3 (cs) 2002-06-12
WO2001005388A2 (fr) 2001-01-25
TR200200065T2 (tr) 2002-10-21
JP4167828B2 (ja) 2008-10-22
CN1915971A (zh) 2007-02-21
BRPI0012387B1 (pt) 2016-11-08
EP1223925A2 (fr) 2002-07-24
DE60031710D1 (de) 2006-12-14
MXPA02000437A (es) 2004-05-21
HUP0202400A2 (hu) 2002-11-28
AR074465A2 (es) 2011-01-19
CN1399548A (zh) 2003-02-26
TWI225398B (en) 2004-12-21
CZ303958B6 (cs) 2013-07-17
HK1048443A1 (en) 2003-04-04
CA2377661C (fr) 2012-05-08
DE60031710T2 (de) 2007-09-06
US20050090556A1 (en) 2005-04-28
EP1223925B1 (fr) 2006-11-02
JP5052423B2 (ja) 2012-10-17
ES2273706T3 (es) 2007-05-16
PT1223925E (pt) 2007-01-31
ATE344027T1 (de) 2006-11-15
HK1048443B (zh) 2007-06-08
KR100750553B1 (ko) 2007-08-20
CN100548977C (zh) 2009-10-14
JP2003504397A (ja) 2003-02-04
AR029381A1 (es) 2003-06-25
AU779936B2 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DK1223925T3 (da) Fedtsyrederivat til behandling af eksterne sekretionslidelser
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
NO20031442D0 (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
DK1028954T3 (da) Substituerede imidazoler egnede til behandling af inflammatoriske sygdomme
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK0967214T3 (da) Intranasale formuleringer til behandling af seksuelle forstyrrelser
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
NO20031443D0 (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
NO20026263L (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
IS7202A (is) Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
DK1434588T3 (da) 2-(amino-3,4-dioxo-1cyclobuten-1-yl)aminoalkylsyrederivater til behandling af smerte
DK1200114T3 (da) PPAR delta inhibitorer til behandling af kardiovaskulære sygdomme
NO20005216D0 (no) Sammensetning for behandling av eksterne sekresjonssykdommer unntatt hypolakrimasjon
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser
NO20022000D0 (no) 6-metoksy-2-naftyleddiksyre-prodrogesammensetninger til behandling av inflammasjon
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser